A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

Hepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen (HBsAg) loss, is recommended as the ideal endpoint of HBV treatment. However, HBsAg loss can be achieved in less than 10% of chronic hepatitis B (CHB) patients treated with current available antiviral drug interferon (IFNα) or nucleos(t)ide analogues (NAs) monotherapy. With the support of the national major special funding for infectious diseases from "11th Five-Year Plan" to "13th Five-Year Plan", we have implemented a pioneer clinical study of sequential combination of IFNα therapy on NAs to treat NAs-treated CHB patients (ie. New Switch Study). This is the world's first clinical trial aiming to functional cure, which increased the rate of HBsAg loss to 15% in the overall population in our study, and to 30-50% among those with lower baseline HBsAg levels. How to further improve the HBsAg loss rate is an urgent issue for us. The key point of achieving functional cure is to reverse the HBV-specific T cell exhaustion and establish the long-term immune control against HBV infection. (Programmed death-1) PD-1/programmed death-ligand 1 (PD-L1) axis blockade has been demonstrated to reinvigorate exhausted CD8+ T cells, and would be a potential strategy to treat chronic HBV infection. In this study, a large multicenter prospective study will be performed to explore the safety and efficacy of a novel combination strategy involving immune checkpoint inhibitor (anti-PD-1 antibody) and IFNα in CHB patients, observe the HBsAg loss rate in NA-treated CHB patients receiving this combination strategy, evaluate the potential of breaking immune tolerance by this strategy, and further assess its efficacy to further improve the clinical cure rate on the basis of New Switch Study. Based on New Switch Study, this study further attempts to reverse T cell exhaustion in CHB patients, explore a novel platform of combination therapy development for clinical cure, and ultimately increase the HBsAg loss rate to higher than 50% in overall patients. The implementation of the project is expected to reduce the burden of HBV infection in China and contribute to the goal of global elimination of hepatitis B and C by 2030 (WHO 2030).

Study Overview

• Status: Recruiting
• Conditions: Chronic Hepatitis b; Anti-PD-1 Antibody; Peg-IFNα
• Intervention / Treatment: Drug: Anti-PD-1 antibody; Drug: NAs; Drug: Peg-IFNα

• Study Type: Interventional
• Enrollment (Estimated): 120
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Dachuan Cai, MD; Phone Number: +86 18323409779; Email: cqmucdc@cqmu.edu.cn
• Study Contact Backup: Name: Min Chen, PhD; Phone Number: +86 17338600343; Email: mchen@hospital.cqmu.edu.cn

Study Locations

• China
  • Chongqing Municipality
    • Chongqing, Chongqing Municipality, China, 400010
      • Recruiting
      • The 2nd affiliated Hospital of Chongqing Medical University
      • Principal Investigator: HONG REN
      • Contact: Dachuan Cai; Phone Number: +8618323409779; Email: cqmucdc@cqmu.edu.cn
      • Contact: HONG REN; Phone Number: +8613983888786; Email: renhong0531@vip.sina.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• 1) Sign the informed consent form before inclusion and be able to complete the study according to the study requirements;
• 2) From inclusion to 30 days after the last administration of the study drug, male subjects or female subjects of childbearing age are willing to voluntarily take effective contraceptive measures;
• 3) 18-70 years old. The weight of male subjects is not less than 45 kg, and the weight of female subjects is not less than 40 kg. Body mass index (BMI) is within the range of 18-32 kg/m^2;
• 4) NAs-naive/NAs-experienced CHB patients.

Exclusion Criteria:

• 1) A history of allergy, or who are suspected by the researcher to be allergic to the active ingredient of the drug under study or its excipients;
• 2) Use of inhibitors, inducers or substrates of CYP3A4 within 28 days before enrollment;
• 3) Systematical use of immunosuppressants, immunomodulators (thymosin) and cytotoxic drugs within 6 months before enrollment, or vaccination of live attenuated vaccine within 1 month before enrollment;
• 4) Acute infection within 2 weeks before enrollment which requires intravenous antibiotic treatment, or existing infection which requires anti-infection treatment when enrollment;
• 5) Clinically significant acute and chronic liver disease not caused by HBV infection (judged by reseachers);
• 6) Confirmed or suspected decompensated cirrhosis, including but not limited to: hepatic encephalopathy, hepatorenal syndrome, bleeding from esophageal varices, splenomegaly, ascites, etc, or evidence of progressive liver fibrosis;
• 7) Primary liver cancer, or alpha-fetoprotein (AFP) is greater than 50 ug/L or imaging suggests the possibility of malignant liver lesions, or other malignant tumors or a history of other malignant tumors within 5 years before enrollment (except that the malignant tumors have been completely relieved after treatment and patients have not received additional medical or surgical intervention within 3 years before screening);
• 8) A history of pathological fracture or osteoporosis;
• 9) Gastrointestinal dysfunction or gastrointestinal diseases that might affect the absorption of oral drugs, such as severe gastric ulcer, erosive gastritis, partial gastrectomy, and persistent gastrointestinal symptoms (such as nausea, vomiting, or diarrhea) >2 grades;
• 10) Serious diseases of circulatory, respiratory, urinary, blood, metabolic, immune, mental, neurological, renal and other systems;
• 11) Major trauma or major surgery within 3 months before enrollment, or planned surgery during the study period;
• 12) Blood donation/loss ≥ 400 mL within 3 months before enrollment, or given a blood transfusion within 3 months before enrollment, or blood donation/loss ≥ 200 mL within 1 month before enrollment;
• 13) Platelet count<90 × 10^9/L, white blood cell count<3.0 × 10^9/L, neutrophil count<1.3 × 10^9/L, total serum bilirubin>2 × upper limit of normal (ULN), albumin<30 g/L, creatinine clearance ≤ 60 mL/min (calculated by CKD-EPI formula), or international normalized ratio of prothrombin time (INR)>1.5 (unless receiving stable anticoagulant therapy);
• 14) Hepatitis C virus (HCV) antibody (+), HIV antigen/antibody (+), or treponema pallidum antibody (+) and rapid plasma regain (RPR) test (+);
• 15) A history of continuous alcohol abuse within 3 years before enrollment (average daily alcohol consumption exceeds 20 gram);
• 16) A history of drug dependence or drug abuse within 1 year before enrollment;
• 17) Those who have participated in clinical trials of other investigational drugs or medical devices and taken investigational drugs or used medical devices within 3 months before enrollment;
• 18) Female in suckling period or pregnancy test (+) during screening;
• 19) Subjects who are considered by the researcher to have other factors that are not suitable for the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1; NAs combined with anti-PD-1 antibody and Peg-IFNα	Drug: Anti-PD-1 antibody; Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection; Drug: NAs; Once/day, 1 capsule/time, oral; Other Names: ETV/TDF/TAF; Drug: Peg-IFNα; Once/week, 180μg/time, subcutaneous injection
Active Comparator: Group 2; NAs combined with Peg-IFNα	Drug: NAs; Once/day, 1 capsule/time, oral; Other Names: ETV/TDF/TAF; Drug: Peg-IFNα; Once/week, 180μg/time, subcutaneous injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serum HBsAg	Serum HBsAg level	Baseline
Serum HBsAg	Serum HBsAg level	24 weeks after the treatment
Serum HBsAg	Serum HBsAg level	48 weeks after the treatment
Serum HBsAg	Serum HBsAg level	24 weeks after the end of treatment
Serum HBV DNA	Serum HBV DNA level	Baseline
Serum HBV DNA	Serum HBV DNA level	24 weeks after the treatment
Serum HBV DNA	Serum HBV DNA level	48 weeks after the treatment
Serum HBV DNA	Serum HBV DNA level	24 weeks after the end of treatment
Serum alanine aminotransferase (ALT)	Serum ALT level	Baseline
Serum ALT	Serum ALT level	24 weeks after the treatment
Serum ALT	Serum ALT level	48 weeks after the treatment
Serum ALT	Serum ALT level	24 weeks after the end of treatment

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Virus and host genome	Detect virus and host genome (focusing on HBV genotype, resistant mutation) using peripheral blood by sequencing	Baseline
Other HBV markers (HBsAb, HBeAg, HBeAb, and HBcAb)	Levels of other HBV markers (HBsAb, HBeAg, HBeAb, and HBcAb)	Baseline
Other HBV markers (HBsAb, HBeAg, HBeAb, and HBcAb)	Levels of other HBV markers (HBsAb, HBeAg, HBeAb, and HBcAb)	24 weeks after the treatment
Other HBV markers (HBsAb, HBeAg, HBeAb, and HBcAb)	Levels of other HBV markers (HBsAb, HBeAg, HBeAb, and HBcAb)	48 weeks after the treatment
Other HBV markers (HBsAb, HBeAg, HBeAb, and HBcAb)	Levels of other HBV markers (HBsAb, HBeAg, HBeAb, and HBcAb)	24 weeks after the end of treatment
Immune response of T and B cells	Frequencies and functions of T and B cells (tested by flowcytometry/FluoroSpot/ELISPOT)	Baseline
Immune response of T and B cells	Frequencies and functions of T and B cells (tested by flowcytometry/FluoroSpot/ELISPOT)	24 weeks after the treatment
Immune response of T and B cells	Frequencies and functions of T and B cells (tested by flowcytometry/FluoroSpot/ELISPOT)	48 weeks after the treatment
Immune response of T and B cells	Frequencies and functions of T and B cells (tested by flowcytometry/FluoroSpot/ELISPOT)	24 weeks after the end of treatment

Collaborators and Investigators

• Sponsor: The Second Affiliated Hospital of Chongqing Medical University
• Collaborators: Guizhou Provincial People's Hospital; First Affiliated Hospital of Chongqing Medical University; The Affiliated Hospital Of Southwest Medical University; Chongqing Three Gorges Central Hospital
• Investigators: Study Director: Hong Ren, MM, The Second Affiliated Hospital of Chongqing Medical University

Study record dates

Study Major Dates

• Study Start (Actual): October 10, 2023
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: February 23, 2023
• First Submitted That Met QC Criteria: March 14, 2023
• First Posted (Actual): March 16, 2023

Study Record Updates

• Last Update Posted (Estimated): September 11, 2025
• Last Update Submitted That Met QC Criteria: September 4, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Blood-Borne Infections; Pathologic Processes; Chronic Disease; Disease Attributes; Infections; Virus Diseases; Digestive System Diseases; Liver Diseases; Hepatitis, Viral, Human; Communicable Diseases; DNA Virus Infections; Hepadnaviridae Infections; Hepatitis, Chronic; Hepatitis; Pathological Conditions, Signs and Symptoms; Hepatitis B; Hepatitis B, Chronic; Physiological Effects of Drugs; Immunologic Factors; spartalizumab; nas
• Other Study ID Numbers: 2023-0221

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No